NCT02976493View on ClinicalTrials.gov

Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

June 18, 2018

Study Completion Date

June 18, 2018

Conditions
Multiple Myeloma
Interventions
OTHER

No Intervention

No Intervention

Trial Locations (1)

162-0822

Local Institution, Shinjuku-ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY